Ren MSc - Demant AS CFO Board
| WILYY Stock | USD 18.77 0.60 3.10% |
Insider
Ren MSc is CFO Board of Demant AS ADR
| Age | 50 |
| Phone | 45 39 17 73 00 |
| Web | https://www.demant.com |
Demant AS Management Efficiency
The company has return on total asset (ROA) of 0.071 % which means that it generated a profit of $0.071 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2752 %, meaning that it generated $0.2752 on every $100 dollars invested by stockholders. Demant AS's management efficiency ratios could be used to measure how well Demant AS manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| M Doherty | Koninklijke Philips NV | 64 | |
| Wilfred Zuilen | Zimmer Biomet Holdings | 54 | |
| Spencer Stiles | Stryker | 47 | |
| Todd Brinton | Edwards Lifesciences Corp | N/A | |
| Alan Douville | Stryker | N/A | |
| Charles Brynelsen | Abbott Laboratories | 63 | |
| A Harrison | Koninklijke Philips NV | 57 | |
| John Liddicoat | Medtronic PLC | 56 | |
| Alejandro Wellisch | Abbott Laboratories | 49 | |
| Peter Loescher | Koninklijke Philips NV | 63 | |
| Marc Koebernick | Siemens Healthineers AG | N/A | |
| Carrie Nichol | Zimmer Biomet Holdings | 40 | |
| Michael Dale | Abbott Laboratories | 61 | |
| Andre Hartung | Siemens Healthineers AG | N/A | |
| Nitin Goyal | Zimmer Biomet Holdings | N/A | |
| Nitin MD | Zimmer Biomet Holdings | N/A | |
| Louis Morrone | Abbott Laboratories | 44 | |
| Vance Brown | Boston Scientific Corp | 54 | |
| Sreelakshmi Kolli | Zimmer Biomet Holdings | 46 | |
| Brett Wall | Medtronic PLC | 58 | |
| Jennifer Kirk | Medtronic PLC | 49 | |
Management Performance
| Return On Equity | 0.28 | |||
| Return On Asset | 0.071 |
Demant AS ADR Leadership Team
Elected by the shareholders, the Demant AS's board of directors comprises two types of representatives: Demant AS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Demant. The board's role is to monitor Demant AS's management team and ensure that shareholders' interests are well served. Demant AS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Demant AS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arne MBA, Pres Board | ||
| Mathias Mller, Head Relations | ||
| Trine KromannMikkelsen, VP Relations | ||
| Niels Wagner, Head of Retail | ||
| Finn Mohring, VP RD | ||
| Sren Nielsen, Pres CEO | ||
| Ren MSc, CFO Board |
Demant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Demant AS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.28 | |||
| Return On Asset | 0.071 | |||
| Profit Margin | 0.11 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 8.18 B | |||
| Shares Outstanding | 446.37 M | |||
| Price To Earning | 36.83 X | |||
| Price To Book | 5.38 X | |||
| Price To Sales | 0.34 X | |||
| Revenue | 19.7 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Demant Pink Sheet Analysis
When running Demant AS's price analysis, check to measure Demant AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Demant AS is operating at the current time. Most of Demant AS's value examination focuses on studying past and present price action to predict the probability of Demant AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Demant AS's price. Additionally, you may evaluate how the addition of Demant AS to your portfolios can decrease your overall portfolio volatility.